T3 Pharma raises more than 12 million Swiss francs
T3 Pharma, a Basel-based biotech company, has closed its second financing round and raised in excess of 12 million Swiss francs in the process. The company’s management has now also been strengthened as it seeks to bring its immuno-oncological product candidates into the clinical development phase.
Research (Img: Alex011973/shutterstock)
T3 Pharma, a spin-off affiliated with the University of Basel, develops immuno-oncological treatment methods to combat tumors. The company, which is supported by BaseLaunch, the healthcare accelerator of BaselArea.swiss, is now intending to enter the clinical development phase. In advance of this, it has now closed a second round of financing, as outlined in a press release. Doing so, T3 Pharma raised more than 12 million francs.
Both existing investors and two new investors in the form of Boehringer Ingelheim Venture Fund (BIFV) and Reference Capital SA took part in the financing round. Simon Ittig, CEO of T3 Pharma, was quoted in the press release: “The support of these investors validates our work and indicates that we are on the right track”.
With the support of its investors and the Biocenter at the University of Basel, the leading product candidates of the Basel-based company are now set to be further developed. The focus is on a bacteria to be inserted into a tumor in order to produce therapeutic proteins within. Claire Barton, recently named Chief Medical Officer of T3 Pharma, will also be involved in this further development in the future. Barton has already worked with the company as a consultant over the past 18 months. Moreover, Frank Kalkbrenner, Managing Director of BIFV, has also been newly elected onto the Supervisory Board at T3 Pharma.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More